The effect of PPAR-α agonism on apolipoprotein metabolism in humans

Atherosclerosis

Volumn 210, Issue 1, 2010, Pages 35-40

  Shah, Ashish ^a   Rader, Daniel J ^a   Millar, John S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Apolipoproteins; HDL; LDL; Lipoprotein metabolism; PPAR alpha; Triglyceride

Indexed keywords

2 [4 [3 [4,5 DIHYDRO 1 (4 METHYLBENZYL) 5 OXO 1H 1,2,4 TRIAZOL 3 YL]PROPYL]PHENOXY] 2 METHYLPROPIONIC ACID; APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; BEZAFIBRATE; CHYLOMICRON; CIPROFIBRATE; CLOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

HUMAN; KINETICS; LIPID METABOLISM; LIPOLYSIS; PRIORITY JOURNAL; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

APOLIPOPROTEINS; APOLIPOPROTEINS A; APOLIPOPROTEINS B; HUMANS; PPAR ALPHA; PROPIONATES; TRIAZOLES;

EID: 77952422358     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.11.010     Document Type: Review

References (39)

1. MacKay J., Mensah G.A. The atlas of heart disease and stroke 2004, World Health Organization, Geneva, Switzerland.
2. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001, 285:2486-2497.
3. Barter P.J., Rye K.A. Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?. Arterioscler Thromb Vasc Biol 2008, 28:39-46.
4. Lambert G., Ancellin N., Charlton F., et al. Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment. Clin Chem 2008, 54:1038-1045.
5. Ge H., Cha J.Y., Gopal H., et al. Differential regulation and properties of angiopoietin-like proteins 3 and 4. J Lipid Res 2005, 46:1484-1490.
6. Vu-Dac N., Gervois P., Jakel H., et al. Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators. J Biol Chem 2003, 278:17982-17985.
7. Dunbar R.L., Rader D.J. Demystifying triglycerides: a practical approach for the clinician. Cleve Clin J Med 2005, 72:661-680.
8. Grundy S.M., Vega G.L. Fibric acids: effects on lipids and lipoprotein metabolism. Am J Med 1987, 83(5B):9-20.
9. Nissen S.E., Nicholls S.J., Wolski K., et al. Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials. JAMA 2007, 297:1362-1373.
10. Terra S.G., Francone O.L., Contant C.F., Gao X., Lewin A.J., Nguyen T.T. Efficacy and safety of a potent and selective peroxisome proliferator activated receptor alpha agonist in subjects with dyslipidemia and type 2 diabetes mellitus. Am J Cardiol 2008, 102:434-439.
11. Berman M., Hall M., Levy R.I., et al. Metabolism of apoB and apoC lipoproteins in man: kinetic studies in normal and hyperlipoproteininemic subjects. J Lipid Res 1978, 19:38-56.
12. Shepherd J., Packard C.J., Stewart J.M., et al. Apolipoprotein A and B (sf 100-400) metabolism during bezafibrate therapy in hypertriglyceridemic subjects. J Clin Invest 1984, 74:2164-2177.
13. Turner P.R., Cortese C., Wootton R., Marenah C., Miller N.E., Lewis B. Plasma apolipoprotein B metabolism in familial type III dysbetalipoproteinaemia. Eur J Clin Invest 1985, 15:100-112.
14. Packard C.J., Clegg R.J., Dominiczak M.H., Lorimer A.R., Shepherd J. Effects of bezafibrate on apolipoprotein B metabolism in type III hyperlipoproteinemic subjects. J Lipid Res 1986, 27:930-938.
15. Watts G.F., Barrett P.H., Ji J., et al. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes 2003, 52:803-811.
16. Bilz S., Wagner S., Schmitz M., Bedynek A., Keller U., Demant T. Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia. J Lipid Res 2004, 45:174-185.
17. Ruel I.L., Lamarche B., Mauger J.F., et al. Effect of fenofibrate on plasma lipoprotein composition and kinetics in patients with complete hepatic lipase deficiency. Arterioscler Thromb Vasc Biol 2005, 25:2600-2607.
18. Tremblay A.J., Lamarche B., Ruel I.L., et al. Effects of fenofibrate on apolipoprotein kinetics in patients with coexisting dysbetalipoproteinemia and heterozygous familial hypercholesterolemia. Atherosclerosis 2006, 188:203-212.
19. Hogue J.C., Lamarche B., Deshaies Y., et al. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia. Metabolism 2008, 57:246-254.
20. Shepherd J., Caslake M.J., Lorimer A.R., Vallance B.D., Packard C.J. Fenofibrate reduces low density lipoprotein catabolism in hypertriglyceridemic subjects. Arteriosclerosis 1985, 5:162-168.
21. Vega G.L., Grundy S.M. Gemfibrozil therapy in primary hypertriglyceridemia associated with coronary heart disease. Effects on metabolism of low-density lipoproteins. JAMA 1985, 253:2398-2403.
22. Stewart J.M., Packard C.J., Lorimer A.R., Boag D.E., Shepherd J. Effects of bezafibrate on receptor-mediated and receptor-independent low density lipoprotein catabolism in type II hyperlipoproteinaemic subjects. Atherosclerosis 1982, 44:355-365.
23. Malmendier C.L., Delcroix C. Effects of fenofibrate on high and low density lipoprotein metabolism in heterozygous familial hypercholesterolemia. Atherosclerosis 1985, 55:161-169.
24. Gaw A., Packard C.J., Caslake M.J., et al. Effects of ciprofibrate on LDL metabolism in man. Atherosclerosis 1994, 108:137-148.
25. Caslake M.J., Packard C.J., Gaw A., et al. Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia. Arterioscler Thromb 1993, 13:702-711.
26. Saku K., Gartside P.S., Hynd B.A., Kashyap M.L. Mechanism of action of gemfibrozil on lipoprotein metabolism. J Clin Invest 1985, 75:1702-1712.
27. Ginsberg H.N. Changes in lipoprotein kinetics during therapy with fenofibrate and other fibric acid derivatives. Am J Med 1987, 83(5B):66-70.
28. Millar J.S., Duffy D., Gadi R., et al. Treatment with a potent and selective PPAR-α agonist, LY518674, significantly increases apoA-I and apoA-II production rates in patients with metabolic syndrome despite no change in HDL. Arteriosler Thromb Vasc Biol 2009, 29:140-146.
29. Hahn S.E., Goldberg D.M. Modulation of lipoprotein production in Hep G2 cells by fenofibrate and clofibrate. Biochem Pharmacol 1992, 43:625-633.
30. Forcheron F., Cachefo A., Thevenon S., Pinteur C., Beylot M. Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients. Diabetes 2002, 51:3486-3491.
31. Schneider J., Schaefer S., Lettgen B., Keiper T., Nawroth P., Dugi K. Siblings with hepatosplenomegaly and lipoprotein lipase deficiency. Lancet 2002, 360:1150.
32. Demant T., Gaw A., Watts G.F., et al. Metabolism of apoB-100-containing lipoproteins in familial hyperchylomicronemia. J Lipid Res 1993, 34:147-156.
33. Naruszewicz M., Mirkiewicz E., Kłosiewicz-Latoszek L. Modification of low density lipoproteins from hypertriglyceridemic patients by macrophages in vitro and the effect of bezafibrate treatment. Atherosclerosis 1989, 79:261-265.
34. Nguyen T.T., Kruckeberg K.E., O'Brien J.F., et al. Familial splenomegaly: macrophage hypercatabolism of lipoproteins associated with apolipoprotein E mutation [apolipoprotein E (delta149 Leu)]. J Clin Endocrinol Metab 2000, 85:4354-4358.
35. Packard C.J., Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol 1997, 17:3542-3556.
36. Schneider A., Stange E.F., Ditschuneit H.H., Ditschuneit H. Fenofibrate treatment inhibits HMG-CoA reductase activity in mononuclear cells from hyperlipoproteinemic patients. Atherosclerosis 1985, 56:257-262.
37. Demant T., Carlson L.A., Holmquist L., et al. Lipoprotein metabolism in hepatic lipase deficiency: studies on the turnover of apolipoprotein B and on the effect of hepatic lipase on high density lipoprotein. J Lipid Res 1988, 29:1603-1611.
38. Taskinen M.R., Sullivan D.R., Ehnholm C., et al. FIELD study investigators. Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate. Arterioscler Thromb Vasc Biol 2009, 29:950-955.
39. Horowitz B.S., Goldberg I.J., Merab J., Vanni T.M., Ramakrishnan R., Ginsberg H.N. Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of high density lipoprotein cholesterol. J Clin Invest 1993, 91:1743-1752.